Catalyst Biosciences terminates CSO Grant Blouse effective Jan 15, 2023

GYRE THERAPEUTICS, INC.

Grant Blouse terminated as Chief Scientific Officer effective January 15, 2023.
Severance per employment agreement plus bonus payments previously disclosed in Dec 27, 2022 8-K.
Blouse will provide consulting services regarding potential sale or license of legacy hemophilia programs.
Company retains Blouse's expertise while reducing executive headcount.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Grant Blouse

Chief Scientific Officer

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2023-01-15
Filed: January 19, 2023, 6:59 PM ET

On January 15, 2023, Catalyst Biosciences, Inc. (the “Company’”) terminated Grant Blouse Ph.D. from his position as the Chief Scientific Officer of the Company, effective as of January 15, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Grant Blouse was terminated as Chief Scientific Officer at GYRE THERAPEUTICS, INC..

Action: terminated
Role: Chief Scientific Officer

Exact text from the filing

On January 15, 2023, Catalyst Biosciences, Inc. (the “Company’”) terminated Grant Blouse Ph.D. from his position as the Chief Scientific Officer of the Company, effective as of January 15, 2023 (the “Effective Date”).

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-002126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.